, Volume 17, Issue 2, pp 653-654
Date: 04 Nov 2009

Caution in Adding Bevacizumab in the Adjuvant Treatment of Breast Cancer

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

To the Editors:

The strategic decision to integrate antiangiogenic agents in the treatment of solid cancers has now become controversial. New preclinical data and clinical trials results have raised questions about the potential harm derived from the administration of the antiangiogenic agent bevacizumab in both clinical practice in the setting of metastatic disease and in clinical trials research in the adjuvant setting.1

Interesting data consistent with recent findings are now reported by Bahri and colleagues.1,2 Given the controversy emerging regarding acquired resistance to bevacizumab, cancer spread, and eventual reduced overall survival for some patients, we would like to comment on the neoadjuvant bevacizumab treatment for breast cancer reported by Bahri and colleagues.2

One protein with a central role in promoting angiogenesis is vascular endothelial growth factor (VEGF). Inhibiting this protein with anti-VEGF agents may limit a tumor’s blood supply and prevent its growth. It soun ...

Published by Springer Science + Business Media, Inc. © 2009 The Society of Surgical Oncology, Inc.